Uzatresgene autoleucel

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers OXFORD, England, March 20, 2025 /PRNewswire/ -- Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1, to treat patients with oesophageal cancer. Dan Menichella is a seasoned biotech executive, who brings extensive experience in vaccine development, strategic partnerships, and rapid corporate growth. As CEO and CBO of CureVac's U.S. subsidiary, he built out the Boston operation, delivered four deals in his first year – including a multi-product cancer vaccine collaboration with Eli Lilly worth up to $1.7 billion. He became CEO of CureVac AG in 2018. Before CureVac, Dan served as CBO at Bamboo Therapeutics, where he spearheaded the in-licensing of a Duchenne muscular dystrophy programme, unlocking the company's $43 million series A and subsequent $645 million buyout by Pfizer. He has significant fundraising experience and led many large transactions, including partnerships with Lilly, Biogen, and Takeda, and supported IPO's and successful exits. Dan's proven ability to forge high-value alliances and advance breakthrough therapeutics underscores his expertise in guiding life science ventures to success. Dan Menichella, incoming Non-Executive Director at Infinitopes, added: "I am honoured to join Infinitopes' Board of Directors at this exciting time for the company, as we begin the Phase I/IIa clinical trial in oesophageal cancer. Infinitopes is a highly innovative company with a strong commitment to cancer research. Its approach holds the promise to revolutionise cancer treatments for patients, and I am excited and committed to support Jonathan and the team as they embark on this groundbreaking path." Jo Brewer, PhD, is a recognised industry leader in cancer immunotherapy and cell therapies, with over 20 years of experience bringing cutting-edge treatments from discovery to the clinic. Currently serving as CSO at Adaptimmune, she has been instrumental in developing autologous and allogeneic T-cell therapies, leading to Tecelra®, the first engineered TCR-T cell therapy for solid tumours to reach the market. As a founding scientist at Adaptimmune, Jo played a critical role in the development of multiple immunotherapies, including lete-cel for sarcoma and uza-cel, now partnered with Galapagos. She has built and led multiple research teams at Adaptimmune and played a significant role in the upscaling from a small biotech to 500+ employees, driving innovation across discovery and translational science. Jo Brewer, PhD, incoming Non-Executive Director at Infinitopes, remarked: "Infinitopes, with its pioneering approach to precision cancer vaccines, driven by its innovative AI/ML-powered Immunomics™ platform, has the potential to revolutionise how we target and treat cancers. The precision and speed that its world-leading clinicians and scientists are advancing its novel immunotherapies is truly impressive, and I look forward to joining the Board at such a critical time of clinical development, to contribute my expertise to bringing these transformative treatments to patients." Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said : "I'm delighted to welcome Dan and Jo to our Board at a pivotal time, as we prepare to begin our first clinical trial for ITOP1, our proof-of-concept cancer vaccine candidate, initially targeting oesophageal cancers. Their leadership and deep expertise in immuno-oncology and biotech growth is invaluable as we advance our AI/ML-driven antigen discovery platform and push the boundaries of what is possible in cancer vaccine development. Their decision to join Infinitopes reflects the strength of our technologies, our ambitious mission, and the future potential impact for patients worldwide." In April 2024 Infinitopes announced its oversubscribed £12.8 million seed financing to advance its AI/ML Precision Immunomics™ bespoke antigen discovery platform. This proprietary technology enables the safe and highly accurate design of 'best-in-class' therapeutics for multiple cancer indications. Guided by an exceptional leadership team and distinguished Scientific Advisory Board (SAB) of world-class clinicians, scientists, and regulatory experts, Infinitopes is poised to initiate its vaccine candidate, ITOP1, in a highly anticipated double-blind, randomised, placebo-controlled Phase I/IIa clinical trial. This trial is aimed at treating patients with oesophageal cancer and is expected to begin at four UK NHS university cancer centres in the first half of 2025. About Infinitopes Infinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading platforms, in precision target discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines against multiple solid tumour indications. The lead vaccine candidate is expected to begin Phase I/IIa trials in H1' 25. Infinitopes has gathered together in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size, nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). Since incorporation, the Infinitopes team has raised nearly $20m from sector expert investors including Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Manta Ray Ventures, Martlet, Meltwind, Octopus Ventures, Saras Capital, Wilbe and the Fundación CRIS Contra el Cáncer, funding its rapid growth from three academic co-founders to 28 full time equivalents. It is now the largest tenant of Oxford University's BioEscalator innovation accelerator. For more information, visit SOURCE Infinitopes WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED